Stoke outlines Q1 2027 rolling NDA start as EMPEROR enrollment targets June, backed by $411M cash balance
Stoke Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $30.47
-8.9% in 7d after detection
Post-detection moves
1h
—
1d
-0.8%
3d
-3.6%
7d
-8.9%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS